Mason Street Advisors LLC lessened its stake in shares of Clorox Co (NYSE:CLX) by 1.4% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 17,914 shares of the company’s stock after selling 251 shares during the quarter. Mason Street Advisors LLC’s holdings in Clorox were worth $2,721,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in the stock. Tower View Investment Management & Research LLC raised its holdings in shares of Clorox by 19.4% during the second quarter. Tower View Investment Management & Research LLC now owns 387 shares of the company’s stock valued at $59,000 after acquiring an additional 63 shares in the last quarter. World Asset Management Inc raised its holdings in Clorox by 0.7% in the second quarter. World Asset Management Inc now owns 9,872 shares of the company’s stock worth $1,512,000 after purchasing an additional 65 shares in the last quarter. Nvwm LLC raised its holdings in Clorox by 1.7% in the third quarter. Nvwm LLC now owns 4,248 shares of the company’s stock worth $645,000 after purchasing an additional 71 shares in the last quarter. Arrow Financial Corp raised its holdings in Clorox by 9.2% in the second quarter. Arrow Financial Corp now owns 892 shares of the company’s stock worth $137,000 after purchasing an additional 75 shares in the last quarter. Finally, Cypress Capital Group raised its holdings in Clorox by 1.8% in the second quarter. Cypress Capital Group now owns 4,312 shares of the company’s stock worth $660,000 after purchasing an additional 75 shares in the last quarter. Institutional investors own 78.56% of the company’s stock.

Shares of NYSE CLX traded down $0.27 during trading on Thursday, reaching $147.02. The company had a trading volume of 46,819 shares, compared to its average volume of 914,181. Clorox Co has a 12-month low of $143.58 and a 12-month high of $167.70. The stock has a market cap of $18.43 billion, a PE ratio of 23.26, a P/E/G ratio of 4.70 and a beta of 0.38. The business’s 50-day moving average is $149.57 and its 200 day moving average is $154.19. The company has a quick ratio of 0.52, a current ratio of 0.87 and a debt-to-equity ratio of 4.69.

Clorox (NYSE:CLX) last released its earnings results on Thursday, October 31st. The company reported $1.59 EPS for the quarter, topping analysts’ consensus estimates of $1.54 by $0.05. Clorox had a return on equity of 123.56% and a net margin of 13.20%. The firm had revenue of $1.51 billion for the quarter, compared to analysts’ expectations of $1.51 billion. During the same period in the prior year, the firm posted $1.62 earnings per share. The company’s quarterly revenue was down 3.6% on a year-over-year basis. On average, analysts anticipate that Clorox Co will post 6.16 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, November 15th. Stockholders of record on Wednesday, October 30th will be paid a $1.06 dividend. The ex-dividend date of this dividend is Tuesday, October 29th. This represents a $4.24 dividend on an annualized basis and a dividend yield of 2.88%. Clorox’s dividend payout ratio is currently 67.09%.

In related news, SVP Michael R. Costello sold 6,997 shares of the stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $162.56, for a total transaction of $1,137,432.32. Following the sale, the senior vice president now directly owns 29,016 shares of the company’s stock, valued at $4,716,840.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Andrew J. Mowery sold 5,648 shares of the stock in a transaction on Monday, November 4th. The shares were sold at an average price of $146.29, for a total value of $826,245.92. Following the sale, the senior vice president now directly owns 15,920 shares in the company, valued at $2,328,936.80. The disclosure for this sale can be found here. Over the last three months, insiders sold 15,870 shares of company stock worth $2,484,000. Insiders own 1.14% of the company’s stock.

A number of equities analysts have issued reports on the company. Cfra downgraded Clorox from a “hold” rating to a “sell” rating in a report on Friday, November 1st. Bank of America decreased their price objective on Clorox from $165.00 to $160.00 and set a “neutral” rating for the company in a report on Thursday, October 3rd. ValuEngine downgraded Clorox from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Morgan Stanley reiterated an “underweight” rating and issued a $134.00 price objective (down previously from $144.00) on shares of Clorox in a report on Monday, September 30th. Finally, Royal Bank of Canada increased their price objective on Clorox to $161.00 and gave the stock a “sector perform” rating in a report on Friday, August 2nd. Five analysts have rated the stock with a sell rating, eight have assigned a hold rating and two have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $152.00.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Cleaning, Household, Lifestyle, and International. The company offers laundry additives, including bleach products under the Clorox brand, as well as Clorox 2 stain fighter and color booster; home care products primarily under the Clorox, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands; naturally derived products under the Green Works brand; and professional cleaning, disinfecting, and food service products under the Clorox, Dispatch, HealthLink, Clorox Healthcare, Hidden Valley, KC Masterpiece, and Soy Vay brands.

Featured Article: Understanding each part of a balance sheet

Institutional Ownership by Quarter for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.